Single-atom Pt-doped ceria nanozymes mitigate myocardial ischemia reperfusion injury via cardiomyocyte-targeted uptake and suppression of reactive oxygen species

Single-atom Pt-doped ceria nanozymes mitigate myocardial ischemia reperfusion injury via cardiomyocyte-targeted uptake and suppression of reactive oxygen species

The primary treatment for myocardial infarction (MI) is restoring blood flow to the obstructed coronary artery. However, this approach can paradoxically generate reactive oxygen species (ROS), leading to secondary ischemia-reperfusion (IR) injury. Multifunctional nanomaterials present a promising al...

Full description

Saved in:
Bibliographic Details
Main Authors: Aoyang Pu, Woo-Sup Sim, Yunseong Ji, Amal George Kurian, Jung-Hwan Lee, Thi Van Anh Bui, Yimin Lai, Hyesoo Hwangbo, Huanhuan Sun, Hae-Won Kim, Hun-Jun Park, Kiwon Ban
Format: Article
Language:English
Published: KeAi Communications Co., Ltd. 2025-11-01
Series:Bioactive Materials
Subjects:
Ceria nanozymes
Myocardial ischemia-reperfusion (IR) injury
Reactive oxygen species (ROS)
Cardiomyocyte-targeted
Antioxidation
Online Access:http://www.sciencedirect.com/science/article/pii/S2452199X25003123
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The primary treatment for myocardial infarction (MI) is restoring blood flow to the obstructed coronary artery. However, this approach can paradoxically generate reactive oxygen species (ROS), leading to secondary ischemia-reperfusion (IR) injury. Multifunctional nanomaterials present a promising alternative for managing IR injury, offering benefits including cost-effectiveness, robust catalytic stability, and customizable properties that surpass traditional antioxidants. This study explores single-atom Pt-doped ceria nanozymes (Pt@CeNZ) with multi-enzyme mimetic functions facilitated by atomically dispersed Pt. The nanozymes effectively eliminate excess ROS in cardiomyocytes, thereby enhancing cell viability. Notably, Pt@CeNZ demonstrates significantly higher uptake in cardiomyocytes, underscoring its potential as a targeted nanotherapeutic for cardiac tissues. In vivo studies further confirm that Pt@CeNZ treatment substantially reduces infarct size and improves cardiac function following IR injury, without inducing long-term toxicity or inflammation. These findings position Pt@CeNZ as a highly promising heart-targeting nanotherapeutic with potential applications in the acute and long-term treatment of cardiac injuries.
ISSN:2452-199X

Similar Items